Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 12/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27993527 | 0.96 | TBXAS1 (0.52) | TBXAS1NAMPTTERTGAAZDHHC20 | |
| SCHEMBL7198930 | 0.91 | TERT (0.49) | TBXAS1NAMPTTERTGAAZDHHC20 | |
| SCHEMBL4373409 | 0.82 | FPR2 (0.37) | TBXAS1NAMPTGAAPBK | |
| SCHEMBL3236452 | 0.81 | FPR2 (0.50) | TBXAS1TERTGAA | |
| SCHEMBL2780861 | 0.80 | TBXAS1 (0.54) | TBXAS1NAMPTTERTPBK | |
| SCHEMBL935332 | 0.79 | TBXAS1 (0.50) | TBXAS1NAMPTTERTPBK | |
| SCHEMBL5142038 | 0.79 | TBXAS1 (0.53) | TBXAS1NAMPTTERTPBK | |
| Hydrochloric Acid SCHEMBL8108651 | 0.78 | TBXAS1 (0.51) | TBXAS1NAMPTTERTPBK | |
| SCHEMBL6314871 | 0.78 | ZDHHC20 (0.41) | TBXAS1GAAZDHHC20ZDHHC2 | |
| SCHEMBL7297042 | 0.78 | TBXAS1 (0.51) | TBXAS1NAMPTTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582684-B2 | Macroporous ion exchange resins | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-09-01 | — | — | US | claimed |
| EP-0707077-B1 | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same | ORTHO CLINICAL DIAGNOSTICS INC (US) | 2004-11-17 | — | — | EP | claimed |
| US-5582988-A | PRECIPITAION OF NUCLEIC ACID AND CATION POLYMER AT ACIDIC PH; ADJUSTMENT OF PH TO RELEASE NUCLEIC ACID | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-12-10 | — | — | US | claimed |
| US-5523368-A | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-06-04 | — | — | US | claimed |
| EP-0707077-A2 | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-17 | — | — | EP | claimed |
| EP-0702006-A1 | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-03-20 | — | — | EP | claimed |
| US-12630582-B2 | Method for biomaterial purification and kits thereof | Life Technologies Corporation (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250367610-A1 | Block Copolymers Grafted to Porous Polymeric Substrate | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4543575-A1 | BLOCK COPOLYMERS GRAFTED TO POROUS POLYMERIC SUBSTRATE | Solventum Intellectual Properties Company (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-2588219-B1 | FILTER PLATE ARTICLE HAVING A WATER-ABSORBENT FILTER ASSEMBLY | NEOGEN FOOD SAFETY US HOLDCO CORP (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240059731-A1 | Method for Biomaterial Purification and Kits Thereof | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-02-22 | — | — | US | disclosed |
| US-20240010674-A1 | A FILTRATION UNIT AND A METHOD FOR BIOMATERIAL PURIFICATION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-01-11 | — | — | US | disclosed |
| WO-2023248020-A1 | BLOCK COPOLYMERS GRAFTED TO POROUS POLYMERIC SUBSTRATE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-12-28 | — | — | WO | disclosed |
| US-5523368-A | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0707077-A2 | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0702006-A1 | Weakly basic polymerizable monomers and polymers prepared therefrom | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0699072-A1 | IRON-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-03-06 | — | — | EP | disclosed |
| US-5487888-A | Iron-binding polymers for oral administration | GELTEX, INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5434270-A | Weakly basic polymerizable monomers and polymers prepared therefrom | EASTMAN KODAK COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1994027621-A1 | IRON-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059731-A1 | Method for Biomaterial Purification and Kits Thereof | BMP2, ADM2, PLOD3 | TBXAS1 2459/4885NAMPT 3388/4885TERT 1545/4885 |
| US-12630582-B2 | Method for biomaterial purification and kits thereof | CD68, FIBP, BMP2 | TBXAS1 3108/4885NAMPT 3608/4885TERT 834/4885 |
| US-20240010674-A1 | A FILTRATION UNIT AND A METHOD FOR BIOMATERIAL PURIFICATION | CD68, PLAUR, BMP2 | TBXAS1 4346/4885NAMPT 4399/4885TERT 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.